Stay updated on Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page.

Latest updates to the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page
- Check3 days agoChange DetectedThe page version was updated from v3.0.1 to v3.0.2, and the old v3.0.1 tag along with the 'Back to Top' element was removed.SummaryDifference0.5%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.5%
- Check17 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and listed countries. These changes enhance the clarity and relevance of the page's content.SummaryDifference55%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.3%
- Check38 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.3%
- Check46 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference4%
Stay in the know with updates to Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page.